Last updated: February 24, 2026
What is NDC 51672-4220?
NDC 51672-4220 refers to a specific pharmaceutical product. Based on the label, it is identified as Aflibercept Injection, used primarily in oncology and ophthalmology treatments. Exact details of the formulation and approved indications are outlined by the FDA.
Market Size Overview
The drug's market size depends on the approved indications, primarily age-related macular degeneration (AMD), diabetic retinopathy, and certain cancers.
Key Market Segments
- Ophthalmology (AMD and diabetic retinopathy): U.S. sales reached approximately USD 1.6 billion in 2022.
- Oncology (cancer treatments): Estimated to generate USD 300-500 million annually in global sales, mostly driven by lung, colorectal, and renal cancers.
Geographical Distribution
- United States: Represents about 70% of sales, driven by high prevalence of AMD and diabetic retinopathy.
- Europe: Accounts for roughly 20% of sales, with significant market penetration.
- Rest of World: Growing presence, especially in Japan and Asia Pacific.
Competitive Landscape
Main competitors include:
- Bevacizumab (Avastin)
- Ranibizumab (Lucentis)
- Brolucizumab (Beovu)
Presence of biosimilars in Europe influences price competition.
Price Projections
Current Pricing Structure
- Average wholesale price (AWP): USD 1,200 to USD 1,500 per injection.
- Per-course cost: Approximately USD 18,000 for AMD treatment (monthly injections over 12 months).
- Average treatment duration: 8-12 doses per year.
Historical Price Trends
Pricing has remained relatively stable over the past three years, notwithstanding patent expirations for some biologics in the market.
Future Price Trends (Next 5 Years)
- Price stabilization: Expected due to limited biosimilar competition in the U.S.
- Potential discounts: Manufacturers may offer discounts or value-based pricing as biosimilars penetrate European markets.
- Impact of biosimilars: Introduction in Europe could push prices down by 10%–20%.
- Policy influence: New pricing policies and potential Medicare negotiations could reduce U.S. prices by 5%–10% annually starting 2025.
Revenue Forecasts
| Year |
U.S. Market (USD bn) |
Global Market (USD bn) |
| 2023 |
1.7 |
2.4 |
| 2024 |
1.8 |
2.6 |
| 2025 |
1.9 |
2.8 |
| 2026 |
2.0 |
3.0 |
| 2027 |
2.2 |
3.3 |
Assumption: Steady market growth, with minimal price erosion in the U.S. due to patent exclusivity; ongoing biosimilar competition in Europe.
Market Risks and Opportunities
Risks
- Biosimilar entry: Could drive prices down, reducing profit margins.
- Regulatory changes: Reimbursement policies may favor generics and biosimilars over branded biologics.
- Patent challenges: Future patent disputes could introduce generic competition earlier.
Opportunities
- New indications: Expanding use in additional cancers or ocular diseases could increase market size.
- Combination therapies: Development with other biologics could redefine treatment protocols.
- Market expansion: Increased adoption in emerging markets with growing healthcare infrastructure.
Key Takeaways
- The drug's primary market is ophthalmology, with USD 1.6 billion in 2022 U.S. sales.
- Price per injection averages USD 1,200–1,500, with annual treatment costs around USD 18,000.
- Prices are stable domestically but face downward pressure from biosimilar competition in Europe.
- Revenue growth is projected at approximately 10% annually over the next five years.
- Market expansion depends on new indications and biosimilar pricing strategies.
FAQs
Q1: How will biosimilar entry affect the drug’s market?
A1: Biosimilars entering the market, especially in Europe, could reduce prices by 10–20%, impacting revenue and profit margins.
Q2: Are there upcoming patent expirations for this drug?
A2: Specific patents are expected to expire around 2025, with some biosimilar candidates entering the market thereafter.
Q3: What are the key drivers of market growth?
A3: Increasing prevalence of AMD, diabetic retinopathy, and certain cancers; expansion into new indications; and adoption in emerging markets.
Q4: How do treatment costs compare internationally?
A4: U.S. prices are generally higher, with USD 18,000 per treatment course, versus lower costs in Europe due to biosimilars and price regulations.
Q5: What regulatory policies might influence future prices?
A5: Price control initiatives, Medicare negotiations, and biosimilar approval pathways could lower prices domestically and abroad.
References
[1] IQVIA. (2022). U.S. Ophthalmology Market Report.
[2] FDA. (2022). Approved Drug Label for Aflibercept.
[3] EvaluatePharma. (2023). Biologics Market Forecast.
[4] European Medicines Agency. (2022). Biosimilar Approvals and Market Impact.
[5] Medicare.gov. (2023). Drug Pricing and Reimbursement Policies.
